1. Immunology/Inflammation
  2. Complement System
  3. Tanruprubart

Tanruprubart  (Synonyms: ANX005)

Cat. No.: HY-P990545 Purity: 99.047%
Technical Support

Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG1 kappa, Isotype Control (HY-P99001). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease.

For research use only. We do not sell to patients.

CAS No. : 2065212-40-8

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG1 kappa, Isotype Control (HY-P99001). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease[1].

Isotype

Human IgG1 kappa

Recommend Isotype Controls
Species Reactivity

Human

IC50 & Target

C1q

In Vitro

Tanruprubart (ANX005) (Titered concentrations) binds with high, comparable affinity to serum-derived C1q from human, cynomolgus monkey, rhesus monkey, dog, and rat, has lower affinity for mouse C1q, and does not bind rabbit C1q[1].
Tanruprubart (Titered concentrations; 1 h) potently inhibits classical complement-mediated hemolysis in human, cynomolgus monkey, rhesus monkey, dog, and rat serum, with an average IC50 of ~350 ng/mL, and does not inhibit hemolysis in rabbit serum[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tanruprubart (ANX005) (10-200 mg/kg; i.v.; once weekly; 4 weeks) administered to Sprague Dawley rats for 4 weeks produces dose-dependent serum and CSF exposures, fully depletes free serum C1q at measurable reagent levels, and shows no treatment-related toxicity at doses up to 200 mg/kg, resulting in a no observed adverse effect level (NOAEL) of 200 mg/kg[1].
Tanruprubart (ANX005) (10-200 mg/kg; i.v.; single bolus dose; once weekly; 4 weeks) administered to cynomolgus monkeys (as single doses or weekly doses for 4 weeks) produces dose-dependent serum and CSF exposures, fully depletes free serum C1q and inhibits complement-mediated hemolysis at measurable reagent levels, fully occupies CSF C1q at higher doses, and shows no treatment-related toxicity at doses up to 200 mg/kg, resulting in a no observed adverse effect level (NOAEL) of 100 mg/kg[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley rats (male and female, young adult, 8-9 weeks old)[1]
Dosage: 10 mg/kg; 50 mg/kg; 100 mg/kg; 200 mg/kg
Administration: i.v.; once weekly; 4 weeks
Result: Depleted free C1q in rat serum at measurable reagent levels.\nShowed dose-proportional increases in serum Cmax; AUC increased greater than dose-proportionally between lower doses, and dose-proportionally between 100 and 200 mg/kg.\nIncreased mean CSF concentrations in a greater-than-dose-proportional manner, with CSF levels representing 0.1% to 0.2% of serum levels on days 38 and 50 of the GLP study.\nExhibited no treatment-related changes in clinical signs, body weight, food consumption, clinical pathology, gross pathology, organ weight, or histopathology at any dose tested.\nAchieved a no observed adverse effect level (NOAEL) of 200 mg/kg.
Animal Model: Cynomolgus monkeys (male and female, 2-4 years old)[1]
Dosage: 15 mg/kg (single bolus); 100 mg/kg (single bolus); 10 mg/kg (weekly x4); 50 mg/kg (weekly x4); 100 mg/kg (weekly x4); 200 mg/kg (weekly x4)
Administration: i.v.; single bolus dose; once weekly; 4 weeks
Result: Depleted free C1q in monkey serum at measurable reagent levels, with free C1q returning to baseline only when reagent levels dropped below detection.\nInhibited ex vivo complement-mediated hemolysis completely at measurable reagent serum levels, with hemolysis activity returning to baseline when reagent levels declined.\nShowed dose-dependent increases in serum concentrations, with trough levels accumulating over weekly doses in the 50, 100, and 200 mg/kg groups (excluding animals with anti-drug antibody responses).\nIncreased mean CSF concentrations with dose, with CSF levels representing 0.04% to 0.11% of serum levels in the non-GLP study, and 0.02% to 0.13% of serum levels in the GLP study on day 29; these CSF levels fully occupied C1q in the CSF at 100 and 200 mg/kg doses on day 29.\nExhibited no treatment-related changes in clinical signs, body weight, food consumption, clinical pathology, gross pathology, organ weight, histopathology, ophthalmic findings, neurologic exams, vital signs, or electrocardiograms at any dose tested.\nAchieved a no observed adverse effect level (NOAEL) of 200 mg/kg.
Gene ID

712  [NCBI]

Accession
Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

145.78 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

Shipping

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Biological Activity
  • Immobilized C1q Protein (HY-NP0194) can bind ANX005. The EC50 for this effect is 2.56 ng/mL.
Purity & Documentation

Purity: 99.047%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tanruprubart
Cat. No.:
HY-P990545
Quantity:
MCE Japan Authorized Agent: